66353-47-7

Basic information

• Product Name: 2,4-Dichlorobutyrophenone
• Synonyms: 2,4-DICHLORO BUTYROPHENONE;2',4'-DICHLOROBUTYROPHENONE;2',4'-DICHLOROPENTANOPHENONE;2,4-DICHLOROPHENYL PROPYL KETONE;1-(2,4-dichlorophenyl)butan-1-one;a,p-DICHLOROBUTYROPHENONE;2,4-Dichlorobutyroph;2,4-Dichlorobenzene butanone
• CAS NO: 66353-47-7
• Molecular Formula: C₁₀H₁₀Cl₂O
• Molecular Weight: 217.09
• EINECS: 613-927-6
• Product Categories: Acetophenone Series
• Mol File: 66353-47-7.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 141 °C / 12mmHg
• Flash Point: 116.849 °C
• Appearance: /
• Density: 1.23
• Vapor Pressure: 0.004mmHg at 25°C
• Refractive Index: 1.5410 to 1.5450
• CAS DataBase Reference: 2,4-Dichlorobutyrophenone(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-Dichlorobutyrophenone(66353-47-7)
• EPA Substance Registry System: 2,4-Dichlorobutyrophenone(66353-47-7)

Safety Data

• Hazardous Substances Data: 66353-47-7(Hazardous Substances Data)

Usage

General Description

2,4-Dichlorobutyrophenone, also known as 2,4-DCBP, is a chemical compound with the molecular formula C10H10Cl2O. It is a white to light yellow solid with a strong odor and is insoluble in water. 2,4-DCBP is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other active substances. It is also used in the production of fragrances and flavors. It is classified as a hazardous substance and is regulated due to its potential impact on human health and the environment. Inhaling or ingesting this chemical can cause irritation to the respiratory and digestive systems, and prolonged exposure can lead to more serious health effects. Therefore, proper safety measures should be taken when handling this compound.

InChI:InChI=1/C10H10Cl2O/c1-2-3-10(13)8-5-4-7(11)6-9(8)12/h4-6H,2-3H2,1H3

Upstream product

• 2234-82-4 1-propylmagnesium chloride 
• 7681-65-4 copper(I) iodide 
• 89-75-8 2,4-dichlorobenzoyl chloride 
• 874-42-0 2,4-dichlorobenzaldeyhde 
• 53066-18-5 1-(2,4-dichlorophenyl)butan-1-ol 
• 927-77-5 n-propylmagnesium bromide 

Downstream Products

• 93363-54-3 1-(2,4-Dichloro-phenyl)-2-hydroxy-2-[1,2,4]triazol-1-ylmethyl-butan-1-one 
• 78967-81-4 C₁₀H₉BrCl₂O 
• 172988-67-9 ethyl 5-(2,4-dichlorophenyl)-4-ethyl-2-methyl-3,5-dioxopentanoate 

Relevant articles and documents

Inhibitors of glycogen synthase kinase 3

New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.

Synthesis, antifungal activity, and molecular modeling studies of new inverted oxime ethers of oxiconazole

Some new oxime ethers of types 7 and 8, in which the methyleneaminoxy group, C=N-O, of oxiconazole 6 is in an inverted atomic sequence, were synthesized and tested for their antifungal activities. Among them, the type 7 compounds, such as the N-ethoxy-morpholino-substituted derivatives 71-o (Table 1), showed good antifungal properties against the Candida strains tested, with minimum inhibitory concentration (MIC) values similar to those of the reference drug 6. A remarkable result was obtained with these types of azoles, which had shown a cidal character against Candida albicans, while the reference drug oxiconazole was only fungistatic in the same tests. This fact may be seen from a comparison of the MIC values with those of the minimum fungicidal concentration (MFC) values for most of the type 7 compounds assayed that have shown differences between the MIC and the MFC, which are lower than three double diluitions. A simple molecular modeling of the P450 14-α-sterol demethylase from C. albicans (Candida P450DM) was built in order to understand how the structural differences between type 7 compounds and oxiconazole 6 can induce different antifungal profiles. The results of this work seem to confirm that it is possible to reverse the atomic sequence of the methyleneaminoxy group, C=N-O, of 6, obtaining new imidazoles possessing good antifungal properties.